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Abstract
Introduction The importance of rational drug therapy is increasing with the aging of the population. Since one of the main
reasons for inappropriate drug prescribing is also the Bage-blind^ approach, which results in ageist practices, this narrative
literature review focuses on the description of the main barriers related to insufficient individualization of drug regimens
associated with such age-blind approaches.
Methodology A narrative literature review using the PubMed, WoS, Embase, and Scopus databases was conducted by the EU
COST Action IS1402. Experts in different scientific fields from six countries (the Czech Republic, Spain, Portugal, Hungary,
Serbia, and Turkey) worked in four specific areas: (1) underrepresentation of older adults in clinical trials and clinical and ethical
consequences; (2) insufficient consideration of age-related changes and geriatric frailty in the evaluation of the therapeutic value
of drugs; (3) frequent prescribing of potentially inappropriate medications (PIMs); and (4) frequent underuse of highly beneficial
nonpharmacological strategies (e.g., exercise).
Results Older patients are underrepresented in clinical trials. Therefore, rigorous observational geriatric research is needed in
order to obtain evidence on the real efficacy and safety of frequently used drugs, and e.g. developed geriatric scales and frailty
indexes for claims databases should help to stimulate such research. The use of PIMs, unfortunately, is still highly prevalent in
Europe: 22.6% in community-dwelling older patients and 49.0% in institutionalized older adults. Specific tests to detect the
majority of age-related pharmacological changes are usually not available in everyday clinical practice, which limits the estima-
tion of drug risks and possibilities to individualize drug therapy in geriatric patients before drug prescription. Moreover, the role
of some nonpharmacological strategies is highly underestimated in older adults in contrast to frequent use of polypharmacy.
Among nonpharmacological strategies, particularly physical exercise was highly effective in reducing functional decline, frailty,
and the risk of falls in the majority of clinical studies.
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Conclusion Several regulatory and clinical barriers contribute to insufficient knowledge on the therapeutic value of drugs in older
patients, age-blind approach, and inappropriate prescribing. New clinical and observational research is needed, including data on
comprehensive geriatric assessment and frailty, to document the real efficacy and safety of frequently used medications.
Keywords Drug prescribing . Older patients . Ageism . Frailty . Age-related changes . Potentially inappropriate medications .
Polypharmacy . Observational studies . Randomized controlled trials
Introduction
The world population is aging and advances in health technol-
ogies and science contribute to increasing longevity and
prolonging of life expectancy in older patients. According to
the World Health Organization (WHO), more than 20% of the
world population will be over 60 years old and, particularly,
the prevalence of very old patients (80+ years) will signifi-
cantly increase by the year 2050 [1].
Unfortunately, drug-related problems in older patients
are very frequent (up to 20–30% of hospitalizations)
and often contribute to higher prevalence of frailty, dis-
ability, morbidity, mortality, and increased healthcare
cost [2–4]. The European project PREDICT (Increasing
the Participation of the Elderly in Clinical Trials, 7th
Framework programme of the European Commission,
2009–2013) confirmed that there is a lack of specific
evidence on the efficacy and safety of frequently used
medications from randomized controlled trials (RCTs)
for older patients, which represent the main medication
users [5]. This problem of Bevidence-biased geriatric
medicine^ creates a substantial barrier to appropriate
drug prescribing in older adults. In 2000, Cohen, in
his paper, confirmed that standard dosing for many fre-
quently used medications recommended by SPCs
(Summary Product Characteristics) should be adjusted
to safer and equally effective low-dose drug regimens
in the majority of older patients [6].
While, until today, ageism in the healthcare society was
understood as systematic stereotyping, unfair treatment of
older people or discrimination against older persons or
certain age groups based on prejudices related to age itself
[7], recent problems with ageism in the area of drug pre-
scribing (conscious or unconscious) relates mainly to the
Bage-blind^ approach [8]. This includes insufficient indi-
vidualization of drug regimens with respect to age-related
physiological, pathological, and pharmacological changes
and with respect to the specific needs of geriatric patients.
This also includes frequent prescribing of potentially inap-
propriate medications (PIMs) in higher age, risky
polypharmacy, unnecessary exposure to medications hav-
ing doubtful efficacy (e.g., pentoxifylline, low-dose pirac-
etam), etc. [8]. Particularly, very old, frail, and disabled
patients are the most disadvantaged group.
This review article focuses mainly on four particular areas
of inappropriate medication use in older patients, namely:
Area 1. Underrepresentation of older adults in clinical
trials, clinical and ethical consequences, and importance
of new evidence from observational research,
Area 2. Insufficient consideration of the impact of age-
related changes and geriatric frailty on the therapeutic
value of drugs in daily clinical practice,
Area 3. Frequent use of high-risk medications in older
patients in different settings of care, and
Area 4. Frequent underuse of some beneficial
nonpharmacological strategies (e.g., physical exercise) in
contrast to high prevalence of polypharmacy and PIM use.
In Central and Eastern Europe, a new scientific program
EUROAGEISM H2020 project was funded for the period
2017–2021, called the FIP7 programme on BInappropriate
prescribing and availability of medication safety and medica-
tion management services in older patients in Europe^. The
aim of this project is to describe the situation in polypharmacy
and inappropriate medication use in older patients in Central
and Eastern Europe (the Czech Republic, Estonia, Lithuania,
Slovak Republic, Hungary, Serbia, Croatia, and Albania) in
comparison to other developed countries (Ireland, Portugal,
Belgium, and Turkey) and some developing countries (India
and Ethiopia) [9].
Methodology
The content of this review article is based on a narrative liter-
ature review conducted with the use of the PubMed, Web of
Science, Embase, and Scopus databases in the period from
April 2015 to October 2018, during the active works of the
WG1b working group BHealthy clinical strategies for healthy
ageing^ under the EU COST Action IS1402 BAgeism - a
multi-national, interdisciplinary perspective^ [10]. In our lit-
erature review, we focused especially on foreign scientific
articles, mostly RCTs, observational studies, and systematic
or narrative literature reviews, published in journals with the
impact factor or peer review journals since 2000. As Bageism^
is not yet recognized by many studies as a specific key word,
we also used other key words selective for areas 1–4 (refer to
the Introduction and corresponding with the Results
subsections). These key words were: ageism, inappropriate
prescribing, inappropriate drug use, potentially inappropriate
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medications, aged, geriatric patients, older patients, frailty,
RCTs, clinical trials, underrepresentation, observational study/
studies, age-related changes, negative outcomes, positive impact,
nonpharmacological methods, physical activity, and physical ex-
ercise. Works on particular areas 1–4 have been summarized by
experts from different fields (geriatric clinical pharmacy, phar-
macology, social pharmacy, physical therapy, nursing, and
pharmacoepidemiology) in cooperation with their local research
teams in six countries (Czech Republic, Spain, Portugal,
Hungary, Serbia, and Turkey).
Works on literature reviews were summarized by indepen-
dently working research teams for sections 1–4, reviewed by
other experts in the working group (minimum 2) and summa-
rized as pre-final and final versions during face-to-face expert
meetings of the EU COST Action IS1402. Cooperating re-
search teams were not asked to record the number of searched
and selected articles and sent to the center mainly pre-final and
final versions of their contributions. Tables 1, 2, and 3 were
summarized also from the identified literature sources.
Results
Underrepresentation of older adults in clinical trials,
clinical and ethical consequences of this
phenomenon, and importance of new evidence
from observational research
It is known that older people respond differently to drug thera-
pies and the risk of adverse drug events (e.g., drug interactions,
adverse drug reactions, and other complications) is higher in this
population due to age-related changes in pharmacokinetics and
pharmacodynamics (for a comprehensive overview of pharma-
cological changes, see Table 1 [11–13]) and also due to frailty,
higher degree of comorbidity, polypharmacy, and other risk fac-
tors [2–4, 14]. Up until now, controlled clinical trials have large-
ly focused on the assessment of single treatment strategies or
strategies applying maximally 2–3 drugs simultaneously, and
mostly on non-geriatric subjects and/or subjects without multi-
ple comorbid conditions. There is evidence of underrecruitment
of older patients in clinical trials, including clinical trials testing
therapies specifically used for the treatment of disorders of older
age [5, 15–17].
Beers and colleagues (2014) from the Medical Center of
Utrecht University reviewed the inclusion criteria of clinical
trials (Phases II–III) performed on recently marketed medi-
cines and concluded that these studies involved a very low
proportion of older adults. Age-related exclusion criteria (co-
morbidity, concomitant medications, etc.) were used particu-
larly in large clinical trials [15]. Surprisingly, an upper age
limit was also applied in Parkinson disease trials, even if
Parkinson’s disease is predominantly a geriatric disorder
[18]. The representation of older adults remained relatively
poor also in clinical trials studying treatment strategies for
solid tumors and hematologic malignancies [19]. For exam-
ple, trials in type 2 diabetes mellitus used an arbitrary upper
age limit for participants in 65.7% of cases, even if this disor-
der is prevalent particularly in older age [20].
This underrepresentation of seniors in clinical trials has
serious consequences for the safe and effective use of medi-
cines in older patients. The problem has been recognized by
the International Council for Harmonization (ICH) guideline
ICH E7 in 1993, and amended by the European Medicines
Agency (EMA) in 2010 [21], which requires the participation
of a desirable proportion of older adults (> 65 years of age) in
clinical trials. This guideline states that Bit would be usually
appropriate to include more than 100 geriatric patients in the
Phase 2 and 3 databases and include patients over the entire
spectrum of the geriatric patient population^ [21]. However,
adherence to these guidelines is still insufficient [22] and,
considering the heterogeneity of the older population, the re-
quested size of at least 100 patients is still highly
underestimated for relevant pharmacoepidemiologic research.
The main reasons for the under-enrollment of older people
in clinical trials are the difficulties in recruiting or retaining
older patients, particularly those with chronic disorders and
several health problems, or ethical problems when investiga-
tors and physicians are reluctant to expose older patients
(mostly with comorbid illnesses and/or advanced disorders)
to experimental, more risky therapies [17, 22]. The enrolment
of older adults in clinical trials, and barriers to their participa-
tion, has gained interest in recent years; for example, the
ROAR program - BRecruiting Older Adults into Research^
(the US program) seeks to raise research awareness and en-
gagement among older adults for participation in clinical trials
for Alzheimer’s disease, and also for other disease conditions
[23].Moreover, the BInterventions on FrailtyWorkingGroup^
developed recommendations on how to screen, recruit, evalu-
ate, and retain frail older people in clinical trials [24, 25].
Underrepresentation of older adults in RCTs contribute to
clinical and ethical dilemmas when prescribing approved
Bstandard dosing/drug therapies^ (tested on substantially
healthier subjects) to geriatric patients [26]. However, with
increasing utilization of e-health records and medication
claims data, the role of observational research is becoming
crucial in order to obtain appropriate answers on the real-life
effectiveness, efficacy, and safety of medications in geriatric
patients, as well as on utilization patterns and new signals of
drug risks [27, 28]. Observational studies, cohort, case–con-
trol, cross-sectional, and outcome studies [29] utilizing differ-
ent data sources (e.g., supplements to registration RCTs, data
from practical clinical trials, patient registries, administrative
claims databases, health surveys, and medical records) [30]
help to answer these questions using real-world data from real
geriatric patients in real conditions [28]. However, the impor-
tant role of confounders in observational studies must be taken
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into consideration, including uncontrolled conditions of med-
ication use by patients [27] (see also Table 1 [27, 31]).
Several examples can be stated from observational studies
on geriatric patients of how risks of medicines or their ineffi-
cacy can be determined. For example, a recent study with a
sample of more than 110,000 older Medicare beneficiaries
conducted by Graham and colleagues published in JAMA in
2016 confirmed that the risk of intracranial bleeding and ex-
tracranial bleeding, including major gastrointestinal bleeding,
was significantly higher after rivaroxaban 20 mg daily com-
pared to dabigatran 150 mg twice daily [32]. Japanese
matched-pair analyses confirmed that, most probably, the saf-
est of these new oral anticoagulants (NOACs) when consid-
ering the risk of major bleeding and any bleeding and com-
parative efficacy to warfarin was apixaban 5/2.5 mg BID,
while dabigatran 150/110mg BID and rivaroxaban 15/10 mg
QD were associated with significantly fewer events of major
bleeding, but not any bleeding compared with warfarin [33].
The observational research and e-health systems open large
possibilities to define the real therapeutic value of drugs in
clinical practice in different subgroups of older patients in
different settings of care with the use of huge study datasets
[34]. In Europe nowadays, the main large medical datasets are
THIN and CPRD (The Health Improvement Network and
Clinical Practice Research Datalink, United Kingdom), the
HSD-CSD-LPD database in Italy (Health Search Database-
Cegedim-Strategic Data-Longitudinal Patient Database), the
IPCI and PHARMO databases in the Netherlands (Integrated
Primary Care Information and PHARMODatabase Network),
the Spanish database for pharmacoepidemiological research in
primary care (BIFAP) or Information System for the
Development of Primary Care Research (SIDIAP) in Spain,
and the Pharmacoepidemiological Research Database
(GePaRD) in Germany [34]. Some of these datasets are also
linked with other data sources (e.g., socioeconomic data of
patients) [27]. However, for future geriatric observational re-
search, of high importance are mainly datasets implementing
information on comprehensive geriatric assessment and frailty
measures, e.g., geriatric datasets of GIFA (Italian Group for
Pharmacoepidemiology) [35], interRAI acute care datasets
(University of Brisbane, Queensland, Australia) [36], and
interRAI integrated geriatric care datasets in Canada (e.g.,
CIHI, Canadian Institute for Health Information, Ontario,
Canada) [37].
Insufficient consideration of the impact
of age-related changes and geriatric frailty
on the therapeutic value of drugs in daily clinical
practice
It is well known that chronological age (65 years and older)
cannot be considered a cut-off point for geriatric age because
chronological aging does not correspond with physiological
aging. There is an extensive inter-individual heterogeneity
among older adults of the same age group in biological age
and this, of course, contributes to substantial heterogeneity in
therapeutic responses and outcomes among older patients
[38]. It is very important to adjust the selection of medications
and dosages with respect to biological age and age-related
changes in drug pharmacokinetics and pharmacodynamics,
of which the most known changes are listed in Table 1
[11–13]. Until now, the highest emphasis has been put on
adjustments of dosing in relation to renal and hepatic func-
tions, but, in the future, a more complex approach in drug
selection and dosing with respect to all individual pharmaco-
logical and physiological changes in geriatric patients is nec-
essary. Even if many age-related changes are known for de-
cades, specific clinical tests enabling their identification are
mostly missing in everyday clinical practice. Thus, they can-
not be identified in advance and preventive measures are very
limited (see Table 2 [11–13]). Because the majority of
healthcare professionals care and will care in the future partic-
ularly for older patients in different settings of care, knowl-
edge of pharmacological changes accompanying aging and
associated drug risks are crucial for all healthcare profes-
sionals [39].
Besides age-related pharmacological changes, geriatric
frailty further increases the heterogeneity in patients’ drug
response in the same age cohort [40] and the concept of
Bfrailty^ has emerged as another measure of Bbiological age^
Table 1 Major characteristics of
randomized controlled trials and
observational studies [27, 31]
Randomized controlled trials Observational studies
Strong internal validity and poor generalizability
(narrow eligibility criteria)
Limited internal validity (confounding and causal
inference), but strong external validity and strong
generalizability
BIdeal setting^ (population with single disease,
experienced providers, centers of excellence)
Real-world setting, provide information on Breal-world^
use and practice, inform clinical practice
Smaller sample Larger sample
Defined period of time Longer follow-up
Limited ability to detect rare and delayed adverse
drug reactions
Can detect signals about the benefits and risks of drugs, rare
and delayed adverse drug reactions, help formulate
hypotheses to be tested in subsequent studies
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Table 2 Major age-related changes in drug pharmacokinetics and pharmacodynamics in older patients, clinical consequences (examples), and
availability of diagnostic tests to identify these age-related changes [11–13]
Age-related anatomical
changes
Age-related functional changes Clinical consequences for the
therapeutic value of drugs in
older patients (examples of
PIMs)
Diagnostic tests available in
daily clinical practice to
identify the age-related change
Central nervous
system
Neuronal losses in different
areas of the brain, about
10–50% (the highest loss of
neurones is usually detected
in gyrus temporalis without
significant impact on
functional status). In the
seventh decade of life, the
weight of the brain is 10%
less than in the third decade.




disorders). Less robust is the
hematoencephalic barrier
and central side effects of
drugs are more pronounced













Higher risk of drug-related
pseudoparkinsonism and
extrapyramidal side effects





No specific tests available to
detect sensitivity to anti-DA
drugs in daily clinical
practice. Monitoring of
short- and long-term drug
response is necessary.




in the number of cholinergic









ACH side effects (cognitive
impairment, deliria,
depression) and/or






must be indicated, if
possible, at the lowest dose




No specific tests available to
detect sensitivity to ACH
drugs in daily clinical
practice. Monitoring of
short- and long-term drug
response is necessary.
Increased response to central
sedative effects of drugs. In
the eighth decade of life, twice
as high sedative response
compared to middle age (third
decade of life) was
documented.
Risk of sedation after







these medications should be
applied.
No specific tests available to
detect sensitivity to sedative
drugs in daily clinical
practice. Monitoring of
short- and long-term drug
response is necessary.






Risk of drug-related depression
after application of centrally
acting sympatholytic drugs




No specific tests available to
detect sensitivity to
sympatholytic drugs in daily
clinical practice. Monitoring









parameters of the heart are
changed; aterosclerotic
processes in the vessel wall
are increased and the
elasticity of vessels is
decreased.
In some seniors, left ventricular
ejection fraction (EF) is
decreased. In healthy older
individuals (due to compen-
satory mechanisms), EF may
stay unchanged even by the
age of 80 years. Minute heart
output is usually decreased
because of pathological
changes (e.g., heart failure).
The vessel resistence
increases, as well as
Risk of orthostatic hypotension
and falls, with subsequent
risk of injuries, fractures,













the risk of orthostasis). Other
specific cardiological tests
(e.g., decrease in EF,
atherosclerotic changes of
coronary vessels, etc).




Age-related functional changes Clinical consequences for the
therapeutic value of drugs in
older patients (examples of
PIMs)
Diagnostic tests available in
daily clinical practice to
identify the age-related change
diastolic blood pressure. The
sensitivity of baroreceptor
sites is significantly decreased
(in both normotensive and
hypotensive patients). This
contributes to the higher risk
and prevalence of orthostatic
hypotension in older age




ability of vessels to
vasoconstriction, etc.).









in vessel walls. Higher risk of
vasoconstriction and
thrombosis in older patients.






direct vasodilating agents is
decreased (e.g., to
pentoxifylline, nootropic
agents, etc.). If they are
recommended, then usually
for short term and in higher,
effective doses.
No specific tests available for
daily clinical practice to
detect responsiveness of







barrier (that mostly does not
significantly influence drug
absorption).
Decrease in intestinal active
transport.
Decrease in absorption of
vitamin D and, partially,
Ca2+, Fe2+, and other ions.
No specific tests available for
daily clinical practice.
Monitoring of lower
plasmatic levels of Fe,
vitamin D, Ca, etc. may be
an indirect test of some
deficits (however, decreased
active intestinal transport
can be only one of the










Prolonged onset of several











Decreased intestinal blood flow. Decreased absorption of drugs
dependent on the magnitude
of intestinal blood flow (e.g.,
furosemide).
No specific tests available for
daily clinical practice.
Decreased gastric acid secretion
and increased levels of gastrin
with increased risk of gastritis
and gastric ulcer. In the group
of 60-year-old persons, basal
achlorhydria was detected in
43% of men and 36% of
women.
Higher age is considered to be
a separate risk factor of
gastropathies. Preventive
therapy (PPI) is indicated
when at least one more
gastrotoxic factor is present,
e.g., use of gastrotoxic drugs
(NSAIDs, methotrexate, and
No specific tests available for








Age-related functional changes Clinical consequences for the
therapeutic value of drugs in
older patients (examples of
PIMs)
Diagnostic tests available in
daily clinical practice to







number of glomeruli, tubular
and vascular changes; men:
prone to development of
benign prostatic
hypertrophia; women:
pelvic relaxation, higher risk
of urine incontinence and
urine infections.
Progressive decline in renal
functions (about 7%/decade)
is documented since the fifth
decade of life. By the age of
70 years, renal function has
reduced by approximately
40% compared to younger
subjects at the age of 30 years.
Glomerular filtration rate
decreases physiologically by
1 mL/min/ year (even in the
absence of cardiovascular,
renal, and acute disorders).
Plasmatic concentration of
albumin stays relatively stable
(with respect to decreased
proportion of muscle tissue
and lower production of
creatinine).
Higher risk of side effects and
clinically significant drug
interactions when
administering drugs that are
highly eliminated renally
(> 80%, e.g., dabigatran).




Ability to concentrate urine is
decreased, as well as
Na+ retention (probably due
to lower excretion of renin).
















Higher concentration of Na+ in
renal tubules, higher excretion
of water.
Decease in total body water by
15–20% when compared to
younger patients (aged
20–30 years), higher risk of
dehydration. Diuretics
should not be administered
as monotherapy in patients
without volume-dependent




(Na+, Cl−, osmotic blood
pressure), daily balance of
water (daily intake of water
and excretion of urine).
Kidneys have lower ability to
sustain blood volume and
proportion of body fluids.
There is a higher risk of
hemodynamic instability in
older patients.
For sufficient blood flow in


















efferens. In sensitive seniors,
their combination may
No specific tests available for
daily clinical practice to
measure renal blood flow.




Age-related functional changes Clinical consequences for the
therapeutic value of drugs in
older patients (examples of
PIMs)
Diagnostic tests available in
daily clinical practice to





Hepatic atrophy begins in the
5th–6th decades of life, but
does not significantly
influence the hepatic func-
tions. The decreased
hepatic perfusion and lower
metabolic capacity of some
hepatic enzymes have the
highest impact on drug
efficacy and safety in older
patients.
Decreased hepatic blood flow
(caused by decreased minute
heart output), significant
decrease in the first-pass effect
of many drugs (by 25–40%).








(by average in 20–40%).




No specific tests available for
daily clinical practice;









significant increase of the
risk of cumulation and
toxicity.
No specific tests available for
daily clinical practice.
Mild decrease in activity of
CYP3A4 in older women
(most probably due to
decrease in estrogen
production).




events and drug interactions
are more significant in older
patients than in younger
adults.















Thorough consideration of all
factors and estimated
risk/benefit of the treatment.
Anticoagulation tests (e.g.,




Decreased production of many
endocrine glands (since the
fifth decade of life).
Decreased production of sexual
hormones (in women, rapid
decrease in menopause; in
men, stable decrease with
aging).
Higher sensitivity to drugs
antagonizing receptors for
sexual hormones, risk of
gynecomastia (e.g., digoxin,
spironolactone).




after repeated stimulation by
food).
Impaired digestion, decreased
tolerance to fatty foods and
sweet foods.
No specific tests used in daily
clinical practice.
Decreased production of thyroid
hormones.
Slowed metabolism, higher
risk of hypothyroidism (e.g.,
after application of
thyrostatic agents).
Thyroid gland function tests.
Decreased secretion of
adrenocortical hormones,
decreased secretion of insulin
in some patients, and/or
decreased glucose tolerance.
Higher risk of diabetes mellitus





Tests of DM or impaired
glucose tolerance.
Immune system Involutional decline in the
function of thymus (crucial
Decreased function of
T-lymphocytes and decreased
Higher risk for infections and
cancers.
No specific tests used in daily
clinical practice.
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and, probably, a better prognostic factor of possible poor
health outcomes. Frail older people are more vulnerable to
adverse drug events/outcomes [40] and the identification of
geriatric frailty is an important predictive factor of possible
adverse drug reactions and events [41].
Frailty is, in general, a term widely used to denote a mul-
tidimensional syndrome of loss of reserves (energy, physical
ability, mobility, cognition, and health) that gives rise to an
increased vulnerability of older persons to stressors (e.g., con-
comitant acute illnesses, hospitalizations, medical procedures)
[42]. Although the biological mechanisms underlying physi-
cal frailty are still scarcely understood, common signs include
fatigue, weight loss, muscle weakness, and progressive de-
cline in physiological functions [43]. Operational criteria to
define physical frailty are based on impairment in several
physiological domains, including mobility, balance, muscle
strength, motor processing, cognition, nutrition (often identi-
fied as nutritional status or weight loss), endurance (including
feelings of fatigue and exhaustion), and physical activity [24].
Assessment of frailty significantly varies among different
tools, which include: (1) frailty phenotype, based on the pres-
ence of 3 out of 5 risk factors (weight loss, exhaustion, low
physical activity, muscle weakness, and slow gait) [40]; (2)
the BRothman^ instrument, which is a modification of the
frailty phenotype including cognition parameters [43]; (3)
frailty scales and indicators, e.g., Clinical Frailty Scale
(CFS); Tilburg Frailty Indicator (TFI); Groningen Frailty
Indicator (GFI); and (4) frailty indexes including the number
of health deficits (e.g., symptoms, signs, disabilities, laborato-




Age-related functional changes Clinical consequences for the
therapeutic value of drugs in
older patients (examples of
PIMs)
Diagnostic tests available in
daily clinical practice to
identify the age-related change
for the maturation of
T-lymphocytes), usually
starting in the fifth decade of
life.
cell immunity. No decrease in
the number of
B-lymphocytes; most




Decrease in proportion of
muscle tissue, by 20% at the
age of 80 years when
compared to the age of
20 years.
Decreased muscle strength,
walking speed (one of the
important markers of geriatric
frailty).
Risk of instability and falls,
higher risk of frailty. Risk of
myositis and
rhabdomyolysis during
treatment with higher doses
of statins, higher toxicity of
digoxin. Low-dose regimens
are recommended.





Increased activity of osteoclasts
and decreased activity of
osteoblasts, increased
osteoresorption (rapid decline
in older women after
menopause).
Higher risk of increased
osteoresorption, osteopenia,
or osteoporosis after






calcium and vitamin D is
recommended.
Tests and clinical assessments
of osteoporosis/osteopenia.
Increase in the proportion of
fatty tissue (in up to 30%).
Accumulation of highly
lipophilic drugs in fatty tissue.
Significantly prolonged
elimination half-life of




The risk of toxicity during
the periods of substantial
weight loss.
No specific tests used in daily
clinical practice.
ACE-Is angiotensin-converting enzyme inhibitors; ACH anticholinergic; ADH antidiuretic hormone; anti-Xa assay anti-factor Xa assay; APPT test
activated partial thromboplastin time test; ARBs angiotensin II receptor blockers; CKD-epi Chronic Kidney Disease Epidemiology Collaboration
equation; DA dopamine, dopaminergic; INR International Normalized Ratio; MDRD Modification of Diet in Renal Disease Study equation; NSAIDs
nonsteroidal anti-inflammatory drugs; SIADH syndrome of impaired secretion of antidiuretic hormone; SSRIs selective serotonin reuptake inhibitors
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Resistance, Ambulation, Illnesses and Loss of weight index)
and others [44, 45]. The EMA recommends the Short Physical
Performance Battery (SPPB) as an instrument to assess physical
frailty in clinical trials, and gait speed as an alternative instrument
[46]. As claims databases and electronic health records became
important sources for observational studies, several tools have
recently been developed to measure geriatric frailty in these
datasets, e.g., Medicare claims-based algorithm of frailty [47],
claims-based frailty index [48], claims-based frailty indicator
[49], electronic frailty index [50], etc. In observational studies,
these tools may help to improve the validity and reduce con-
founding when adverse drug outcomes are tested.
Frailty measures have also been utilized in first observa-
tional studies providing information on the efficacy and safety
of drug therapies particularly in frail older patients. An obser-
vational study by Pilotto and colleagues showed that statins
reduced the 3-year mortality rate even in frail older persons
with cardiovascular disorders [51]. Martinez and colleagues
compared, in an observational study, apixaban, dabigatran,
and rivaroxaban versus warfarin in frail older patients with
nonvalvular atrial fibrillation, and concluded (in contradiction
to findings in the previous section) that only rivaroxaban was
associated with reduced risk of stroke or systemic embolism
and there were no significant differences in the risk of major
bleeding for NOACs when compared to warfarin [52]. In an-
other study using frailty tools, Droz and colleagues evaluated
the efficacy and tolerability of taxane therapy in senior adults
with chemonaïve metastatic castration-resistant prostate can-
cer and found that frail patients experienced more toxicity
events but still gained significant clinical benefit from taxane
therapy [53]. In another study, antidepressant use in not frail
older women was associated with increased risk of incident
frailty after 3 years [54].
It has also been described that the use of PIMs in older
patients may contribute to a decline in physical performance
and functional autonomy. Many of these PIMs cause frequent
peripheral and central side effects [55–57] and may aggravate
or worsen geriatric symptoms and syndromes (e.g., depres-
sion, cognitive impairment, urinary incontinence, weight loss,
malnutrition, etc.) [55–59]. Interaction between the processes
and exposure to PIMs may speed up the manifestation of
geriatric frailty [58–60]. Some geriatric studies confirm that
PIMs are often prescribed to frail older adults and frailty has
also been documented as a specific risk factor or predictor of
PIM use [59, 60].
Comprehensive geriatric assessment and care management
including the assessment of geriatric frailty has already shown a
benefit by reducing suboptimal prescribing in frail older inpa-
tients and outpatients, and by reducing serious adverse drug
reactions [61]. However, we still know little about how to indi-
vidualize drugs with respect to the degree of geriatric frailty,
and geriatric teaching books still mostly recommend Bhigher
cautiousness^ and the Bstart low-go slow^ approach [62].
Frequent use of high-risk medications in older
patients in different settings of care
Many explicit criteria of PIMs in older patients have been
developed in the past 25 years, e.g., Beers criteria 2015 [55],
STOPP/START criteria [56], Australian medication use and
prescribing indicators [63], NORGEP criteria [64], PRISCUS
and FORTA criteria [65], and others, to assist prescribers in
the identification of high-risk medications in older patients
and to help them reduce the excessive and unnecessary pre-
scribing of such medications. Also, drugs having poor effica-
cy in older age (mostly due to processes of aging) are included
on the lists of PIMs [55, 56, 63–65].
Despite the first explicit criteria of PIMs being published
more than 20 years ago and updated many times since (at the
last time in the year 2015) [55] and despite the development of
national variations of these criteria in many countries [56,
63–65], epidemiological findings still confirm the highly
prevalent use of PIMs in older adults in different settings of
care, in up to 84.5% in acute care [60], up to 62.4% in nonin-
stitutionalized seniors in the community (using five or more
medications) [66], or up to 70% in older residents in nursing
homes [67]. According to two systematic reviews, the weight-
ed prevalence of the use of PIMs in Europe was 22.6% in
community-dwelling older adults and 49.0% in institutional-
ized older people, with substantial variations across study sites
and countries [68, 69]. Two larger studies using claims data-
bases examined the trends of the use of PIMs in the outpatient
setting in Ireland and in the USA (1997–2012), and showed
that the prevalence of PIMs slightly increased in Ireland from
32.6% to 37.3% and decreased in the USA from 64.9% to
56.6% [70, 71]. Many of the adverse drug reactions of PIMs
mimic geriatric syndromes (e.g., impaired cognition, instabil-
ity and falls, malnutrition, etc.) or may cause or aggravate
various geriatric problems (e.g., renal insufficiency, short
memory impairment, severe bradycardias, sedation, and
others) [55, 56, 60]. Despite contradictory findings, exposure
to PIMs led, in some studies, to higher occurrence of geriatric
symptoms, syndromes, and geriatric frailty, increased hospi-
talizations, healthcare costs, and decreased quality of life
[57–59, 72–74].
Some publications show that PIMs are more likely to be
prescribed in disadvantaged older patients or in older pa-
tients at higher risk of adverse drug events/outcomes.
Older adults using polypharmacy, psychotropic drugs, or
geriatric patients suffering from polymorbidity are more
likely to be exposed to PIMs [75–77]. Factors associated
with socioeconomic problems or lower socioeconomic sta-
tus (e.g., having poor economic situation, not having infor-
mal carer, etc.) [76] were also significantly associated with
PIM use, as well as signs of inadequate care management
or care risks (e.g., having more than one prescriber [78],
frequent physician visits [77], longer stay in nursing homes
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[68, 79], longer hospital stay [80], etc.). Based on findings
of our European multicentric project ADHOC (BAgeD in
Home Care^), the odds of being prescribed at least one
PIM increased exponentially with increasing number of
risk factors for adverse drug events [76].
Deprescribing, defined as the Bprocess of withdrawal of an
inappropriate medication, supervised by a health care profes-
sional with the goal of managing polypharmacy and improv-
ing outcomes^, can be used to reduce exposure to PIMs and to
improve older patients’ safety and health outcomes [81].
Various tools of deprescribing have been published to date,
e.g., specific guidelines for deprescribing, different risk scores
and clinical prediction tools helping to estimate individual risk
of adverse drug events, scales enabling to identify individual
anticholinergic and sedative medications burden, and implicit
and explicit criteria of inappropriate prescribing [82]. Fifteen
deprescribing tools have been already specifically developed
for frail older patients or for older adults with limited life
expectancy (e.g., Screening Tool of Older Persons
Prescriptions in Frail adults with limited life expectancy,
STOPPFrail) [83] [84]. However, a systematic review and
meta-analysis of studies published by Page et al. in 2016
showed conflicting results on the impact of deprescribing on
older patients’ mortality. While the mortality of older adults
has been reduced in nonrandomized studies, no reduction was
found in RCTs (except for a subgroup of RCTs analyzing non-
educational patient-specific deprescribing interventions) [85].
Frequent underuse of some beneficial
nonpharmacological strategies (e.g., physical
exercise) in contrast to high prevalence
of polypharmacy and PIM use
Even if the primary goal of this article was to emphasize issues
related to inappropriate drug prescribing with respect to as-
pects of ageism, this short subsection is devoted to the
underuse of some highly beneficial nonpharmacological strat-
egies (e.g., physical exercise) in contrast to the frequent over-
use of PIMs and polypharmacy. This subsection does not fo-
cus on all nonpharmacological interventions (e.g., other
physiotherapeutic methods, occupational therapy, speech, lan-
guage therapy, and nutritional therapy), as this was not a pri-
mary goal of this article [86], neither does it consider patient
medication adherence and persistence, which are the other
biggest issues of rational drug treatment [87].
There is clear, strong epidemiological evidence indicating
that some nonpharmacological approaches, e.g., regular phys-
ical activity, have an important preventive effect associated
with reduced rates of all-cause mortality and morbidity [88].
Regular aerobic exercise is one of the most potent strategies to
preserve vascular functions with advancing age; other phar-
maceutical and nutraceutical strategies can only help to further
delay, minimize, or prevent arterial aging [89]. Increase in
exercise capacity (increase in each one metabolic equivalent
during the exercise) is associated with a 16% mean reduction
in all-cause and CVS mortality in older adults [90]. These
results correspond favorably with the survival benefit reached
by the secondary prevention of myocardial infarction with the
use of low-dose aspirin, statins, beta-blockers, and
angiotensin-converting enzyme inhibitors [91].
Particularly, physiological functions can be preserved or
improved by regular exercise and the prevalence of several
disorders is significantly reduced, e.g., hypertension, stroke,
metabolic syndrome, type 2 diabetes, breast and colon cancer,
depression, the risk of falling, etc. [88]. A systematic review
by Lozano-Montoya and colleagues showed that exercise in-
terventions alone or with nutritional supplementation may im-
prove physical performance in community-dwelling older pa-
tients with physical frailty and sarcopenia, but further well-
designed studies are needed on this topic to also confirm the
effectiveness of such interventions [92]. An RCT published
by Martínez-Velilla and colleagues also showed that exercise
can reverse functional decline in hospitalized older patients
[93].
Moreover, polypharmacy and some medications may neg-
atively influence functional capacity and physical activity
(e.g., benzodiazepines, Z-drugs, other hypnosedatives, older
generations of antidepressants, antipsychotics, etc. that are
also stated on the lists of PIMs). According to the study of
Heseltine and colleagues, every additional medication pre-
scribed (OR 1.069, CI 1.016–1.124) increased the likelihood
of being categorized as sedentary [94]. The results of walking
speed and grip strength tests were also inversely associated
with polypharmacy [95].
Contradictory are findings of studies testing the impact of
physical exercise on cognitive functioning. Two systematic
reviews published showed no evidence of the benefit of exer-
cise on cognitive performance in older patients without cog-
nitive impairment and with dementia [96, 97]. The only ben-
efit in older patients having dementia was the improvement in
the ability to perform activities of daily living, although the
quality of this evidence was low [96]. A review of studies
summarized by Santos-Lozano and colleagues described that
regular physical activity may prevent the development of
Alzheimer’s disease in older persons, but further rigorous re-
search is needed [98].
In Table 3, we summarized, as an example, the effective-
ness of some nonpharmacological, pharmacological, and
combined interventions in preventing falls in older people in
different settings of care. The findings are based on two
Cochrane systematic reviews [99, 100] that confirmed the
predominant positive role of exercise and, partially, also vita-
min D supplementation.
Among available therapeutic strategies, regular physical
activity is a potent Bhealthy clinical strategy for healthy
aging^, particularly in community-residing older adults. In
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real cl inical pract ice, the important role of this
nonpharmacological strategy is highly underestimated and
not always recommended by prescribing physicians.
Appropriate exercise is available at low cost and relatively
free of adverse effects [101]. It decreases the rapidity of aging,
all-cause morbidity, and mortality. On the other hand, strate-
gies helping to reduce the burden of polypharmacy and, par-
ticularly, long-term exposition to PIMs may also help to in-
crease the physical activity in older patients.
Limitations
The first limitation of our article is that, in our narrative liter-
ature review, we focused only on a general overview of newer
research findings for four particular areas listed in the
Methodology section. Secondly, as the narrative literature re-
view method was selected, we did not follow any strict guide-
lines for conducting systematic literature reviews. This ap-
proach introduces bias, as well as the fact that we mainly
focused on newer RCTs, observational studies, and literature
reviews published after the year 2000. Thirdly, even if works
on specific subsections have been conducted and reviewed by
experts in particular professional areas, specific selection of
articles might lead to another bias. Lastly, while the aim of our
article was to emphasize important problems of safe medica-
tion prescribing in older adults directly or indirectly linked to
aspects of ageism, ageism is not a frequently used key word in
the study databases, so we also selected articles using other
key words related to safe and effective medication use in older
adults.
Conclusion
Rational prescribing in older patients is accompanied bymany
clinical and ethical dilemmas and problems that directly or
indirectly result from or in ageist practices. Clinical guidelines
are often non-geriatric and evidence from recent studies do not
yet provide clear answers on how to specifically individualize
drug treatment (dosing, drug combinations, etc.) with respect
to all age-related pharmacological and physiological changes
and different stages of geriatric frailty. Clinical tests that may
help to identify important age-related changes are mostly non-
specific or missing in daily clinical practice and cannot sup-
port enough highly individualized drug treatment. Moreover,
new rigorous geriatric evidence is necessary not only from
randomized controlled trials (RCTs), but also from geriatric
observational studies. Aging of the population creates a new
challenge for research and clinical practice that should focus
more on effect ive and safe pharmacological and
nonpharmacological interventions in specific cohorts of geri-
atric patients. Moreover, e-health and information technolo-
gies, data sharing between different settings of care, and al-
ready higher emphasis on individualized drug treatment in
Table 3 Examples of the effectiveness of some nonpharmacological, pharmacological, and combined interventions in preventing falls in older patients
[99, 100]
Community Care facilities Hospitals















Uncertain effect Uncertain effect
Vitamin D* Does not appear to reduce,
but may be effective
in people who have
lower vitamin D levels
before treatment
Does not appear to reduce,
but may be effective in
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Uncertain effect Uncertain effect
Multifactorial intervention is a multiple-component intervention with individual assessment of risk
Multiple intervention is a multiple-component intervention without individual assessment of risk
*Vitamin D may be considered not only as pharmacological intervention, but also as nutritional intervention
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older patients will speed up the process of geriatrization of
medicine and pharmacy.
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